Anquor Corporate Finance
TTR ID Profile: 149403
|
|
Número de Empleados: 1-10
Inicio de Actividad: 2019
Website:
www.anquorcf.com
E-mail:
contact@anquorcf.com
LinkedIn: ver perfil
Avenida Diagonal, 361, 2º 2ª
08037
Barcelona, Cataluña, España
Tel.: +34 933 906 191
Otras Oficinas (2)
Última actualización en: 06 Jun 2025
Datos Principales
Breve Descripción
Asesor financiero.
Nombre
Anquor Corporate Finance
Inicio de Actividad
2019
Tipo de Entidad
Asesor Financiero / Auditora
Estado Corporativo
Nombre Jurídico
Anquor Corporate Finance, S.L.
CIF / NIF / CNPJ / TAX ID
B88486907
Representación de Capital Social
Sociedad Limitada
País - Estado / Provincia / Región
España - Cataluña
Principales Ejecutivos y Profesionales
| Nombre | Cargo | ||
|---|---|---|---|
| Pascal Vieilledent | Founder & CEO - Chief Executive Officer | pascal@anquorcf.com | vCard |
| Pauline Houl | Managing Partner | - | |
| Álvaro Bailo | Partner | alvaro.bailo@anquorcf.com | vCard |
| Antonio Bela | Partner | antonio.bela@anquorcf.com | vCard |
| Emilia Martínez | Partner | emilia.martinez@anquorcf.com | vCard |
| Gabriel Mesquida | Partner | gabriel.mesquida@anquorcf.com | vCard |
| Josep Aiguade | Partner | josep.aiguade@anquorcf.com | vCard |
| Josep María Piqueras | Partner | - | |
| Marc Cebrian | Partner | marc.cebrian@anquorcf.com | vCard |
| Patrick Sabaté | Partner | patrick.sabate@anquorcf.com | vCard |
| Pere Colomer | Partner | pere.colomer@anquorcf.com | vCard |
| Simon Lepage | Partner | simon.lepage@anquorcf.com | vCard |
| Alex Moragas | Associate | alex.moragas@anquorcf.com | vCard |
| Martí Puig Malaret | Senior Analyst | marti.puig@anquorcf.com | vCard |
| Bruno Cosano Solá | Analyst | bruno.cosano@anquorcf.com | vCard |
Mergers & Acquisitions
| Fecha | Target | País | Comprador | Vendedor | IMPORTE (EURm) | Sector | |||
|---|---|---|---|---|---|---|---|---|---|
|
25 Mar 2025
Completada
|
Laboratório Edol | Portugal | Faes Farma | Accionistas Particulares I |
65,00 (Aprox.) |
30.01.03 Pharmaceutical R&D, Manufacturing & Distribution 30 Healthcare / 30.01 Biotechnology & Pharmaceuticals |
 |
|
|
|
07 Nov 2024
Completada
|
Bebegel Business | Portugal | Theralab | Cooper Consumer Health | ND |
30.01.03 Pharmaceutical R&D, Manufacturing & Distribution 30 Healthcare / 30.01 Biotechnology & Pharmaceuticals |
|
||
|
11 Jul 2024
Completada
|
Agsa | España | Everwood Capital | Accionistas Particulares I | ND |
35.09.02 Ports 35 Industrials / 35.09 Transport Infrastructure |
|
||
|
11 Sep 2023
Completada
|
Mabo Farma | España | PharmaS | Accionistas Particulares I | ND |
30.01.03 Pharmaceutical R&D, Manufacturing & Distribution 30 Healthcare / 30.01 Biotechnology & Pharmaceuticals |
|
|
|
|
27 Mar 2023
Completada
|
Apexfarma, Cross Pharm | Suiza, España | Piex | Accionistas Particulares I | ND |
10.02.01 Advertising & Marketing Services 10 Business Services / 10.02 Marketing & Advertising 30.01.03 Pharmaceutical R&D, Manufacturing & Distribution 30 Healthcare / 30.01 Biotechnology & Pharmaceuticals |
|
Private Equity
| Fecha | Target | País | Comprador | Vendedor | IMPORTE (EURm) | Sector | |||
|---|---|---|---|---|---|---|---|---|---|
|
11 Jul 2024
Completada
|
Agsa | España | Everwood Capital | Accionistas Particulares I | ND |
35.09.02 Ports 35 Industrials / 35.09 Transport Infrastructure |
|
||
|
12 Sep 2022
Completada
|
Vesismin Health | España | Schülke | Accionistas Particulares I | ND |
55.02.04 Pharmaceutical & Personal Care Chemicals 55 Raw Materials & Natural Resources / 55.02 Chemicals |
|
|